The role of syndecans in disease and wound healing

Matrix Biology

Volumn 25, Issue 7, 2006, Pages 443-456

  Fears, Constance Y ^a   Woods, Anne ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Angiogenesis; Disease; Heparan sulfate proteoglycan; Shedding; Syndecan

Indexed keywords

PROTEOHEPARAN SULFATE; SYNDECAN 2; SYNDECAN 4;

ANGIOGENESIS; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BODY WEIGHT; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL MOTILITY; DISEASE MARKER; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; FOOD INTAKE; FUNCTIONAL PROTEOMICS; HEART VENTRICLE REMODELING; HUMAN; IN VITRO STUDY; OBESITY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SIGNAL TRANSDUCTION; TISSUE INJURY; TISSUE REPAIR; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR GROWTH; VIRUS INFECTION; VIRUS VIRULENCE; WOUND HEALING;

ANIMALS; BACTERIAL INFECTIONS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; OBESITY; SYNDECANS; VIRUS DISEASES; WOUND HEALING;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 33749441307     PISSN: 0945053X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.matbio.2006.07.003     Document Type: Review

References (169)

1. Adams J.C., Kureishy N., and Taylor A.L. A role for syndecan-1 in coupling fascin spike formation by thrombospondin-1. J. Cell Biol. 152 (2001) 1169-1182
2. Albrecht E.W., Stegeman C.A., Heeringa P., Henning R.H., and van Goor H. Protective role of endothelial nitric oxide synthase. J. Pathol. 199 (2003) 8-17
3. Alexander C.M., Reichsman F., Hinkes M.T., Lincecum J., Becker K.A., Cumberledge S., and Bernfield M. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat. Genet. 25 (2000) 329-332
4. Andrian A., Greenier D., and Rouabhia M. Porphyromonas gingivalis lipopolysaccharide induces shedding of syndecan-1 expressed by gingival epithelial cells. J. Cell. Physiol. 204 (2005) 178-183
5. Anttonen A., Heikkila P., Kajant I.M., Jalkanen M., and Joensuu H. High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery. Lung Cancer 32 (2001) 297-305
6. Armstrong L.C., and Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol. 22 (2003) 63-71
7. Barbareschi M., Maisonneuve P., Aldovini D., Cangi M.G., Pecciarini L., Mauri F., Veronese S., Caffo O., Lucenti A., Palma P.D., Galligioni E., and Doglioni C. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 98 (2003) 474-483
8. Bayer-Garner I.B., Dilday B., Sanderson R.D., and Smoller B.R. Syndecan-1 expression is decreased with increasing aggressiveness of basal cell carcinoma. Am. J. Dermatopathol. 22 (2000) 119-122
9. Bayer-Garner I.B., Sanderson R.D., Dhodapkar M.V., Owens R.B., and Wilson C.S. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod. Pathol. 14 (2001) 1052-1058
10. Beauvais D.M., and Rapraeger A.C. Syndecan-1-mediated cell spreading requires signaling by alphavbeta3 integrins in human breast carcinoma cells. Exp. Cell Res. 286 (2003) 219-232
11. Beauvais D.M., and Rapraeger A.C. Syndecans in tumor cell adhesion and signaling. Reprod. Biol. Endocrinol. 2 (2004) 3
12. Bein K., and Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J. Biol. Chem. 275 (2000) 32167-32173
13. Bellin R., Capila I., Lincecum J., Park P.W., Reizes O., and Bernfield M.R. Unlocking the secrets of syndecans: transgenic organisms as a potential key. Glycoconj. J. 19 (2003) 295-304
14. Birch M.A., and Skerry T.M. Differential regulation of syndecan expression by osteosarcoma cell lines in response to cytokines but not osteotropic hormones. Bone 24 (1999) 571-578
15. Bjorbaek C., and Hollenberg A.N. Leptin and melanocortin signaling in the hypothalamus. Vitam. Horm. 65 (2002) 281-311
16. Bobardt M.D., Saphire A.C., Hung H.C., Yu X., Van der Schueren B., Zhang Z., David G., and Gallay P.A. Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 18 (2003) 27-39
17. Bousarghin L., Touze A., Combita-Rojas A.L., and Coursaget P. Positively charged sequences of human papillomavirus type 16 capsid proteins are sufficient to mediate gene transfer into target cells via the heparan sulfate receptor. J. Gen. Virol. 84 (2003) 157-164
18. Brule S., Charnaux N., Sutton A., Ledoux D., Chaigneau T., Saffar L., and Gattegno L. The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF- 1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 16 (2006) 488-501
19. Burbach B.J., Ji Y., and Rapraeger A.C. Syndecan-1 ectodomain regulates matrix-dependent signaling in human breast carcinoma cells. Exp. Cell Res. 300 (2004) 234-247
20. Carroll L., Voisey J., and van Daal A. Mouse models of obesity. Clin. Dermatol. 22 (2004) 345-349
21. Chakravarti R., Sapountzi V., and Adams J.C. Functional role of syndecan-1 cytoplasmic V region in lamellipodial spreading, actin bundling, and cell migration. Mol. Biol. Cell 16 (2005) 3678-3691
22. Chang C., and Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 11 (2001) S37-S43
23. Chang Z., Meyer K., Rapraeger A.C., and Friedl A. Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ. FASEB J. 14 (2000) 137-144
24. Chen H., Strickland D.K., and Mosher D.F. Metabolism of thrombospondin 2. Binding and degradation by 3t3 cells and glycosaminoglycan-variant Chinese hamster ovary cells. J. Biol. Chem. 271 (1996) 15993-15999
25. Chen D., Adenekan B., Chen L., Vaughan E.D., Gerald W., Feng Z., and Knudsen B.S. Syndecan-1 expression in locally invasive and metastatic prostate cancer. Urology 63 (2004) 402-407
26. Chen E., Hermanson S., and Ekker S.C. Syndecan-2 is essential for angiogenic sprouting during zebrafish development. Blood 103 (2004) 1710-1719
27. Chen L., Klass C., and Woods A. Syndecan-2 regulates transforming growth factor-beta signaling. J. Biol. Chem. 279 (2004) 15715-15718
28. Chen Y., Abraham D.J., Shi-Wen X., Pearson J.D., Black C.M., Lyons K.M., and Leask A. CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol. Biol. Cell 15 (2004) 5635-5646
29. Chernousov M.A., and Carey D.J. N-syndecan (syndecan 3) from neonatal rat brain binds basic fibroblast growth factor. J. Biol. Chem. 268 (1993) 16810-16814
30. Clasper S., Vekemans S., Fiore M., Plebanski M., Wordsworth P., David G., and Jackson D.G. Inducible expression of the cell surface heparan sulfate proteoglycan syndecan-2 (fibroglycan) on human activated macrophages can regulate fibroblast growth factor action. J. Biol. Chem. 274 (1999) 24113-24123
31. Clayton A., Thomas J., Thomas G.J., Davies M., and Steadman R. Cell surface heparan sulfate proteoglycans control the response of renal interstitial fibroblasts to fibroblast growth factor-2. Kidney Int. 59 (2001) 2084-2094
32. Conejo J.R., Kleeff J., Koliopanos A., Matsuda K., Zhu Z.W., Goecke H., Bicheng N., Zimmermann A., Korc M., Friess H., and Buchler M.W. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int. J. Cancer 88 (2000) 12-20
33. Contreras H.R., Fabre M., Granés F., Casaroli-Marano R., Rocamora N., Herreros A.G., Reina M., and Vilaró S. Syndecan-2 expression in colorectal cancer-derived HT-29 M6 epithelial cells induces a migratory phenotype. Biochem. Biophys. Res. Commun. 286 (2001) 742-751
34. Cornelison D.D., Filla M.S., Stanley H.M., Rapraeger A.C., and Olwin B.B. Syndecan-3 and syndecan- 4 specifically mark skeletal muscle satellite cells and are implicated in satellite cell maintenance and muscle regeneration. Dev. Biol. 239 (2001) 79-94
35. Couchman J.R. Syndecans: proteoglycan regulators of cell-surface microdomains?. Nat. Rev., Mol. Cell Biol. 4 (2003) 926-937
36. Davies E.J., Blackhall F.H., Shanks J.H., David G., McGown A.T., Swindell R., Slade R.J., Martin-Hirsch P., Gallagher J.T., and Jayson G.C. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin. Cancer Res. 10 (2004) 5178-5186
37. Deindl E., Hoefer I.E., Fernandez B., Barancik M., Heil M., Strniskova M., and Schaper W. Involvement of the fibroblast growth factor system in adaptive and chemokine-induced arteriogenesis. Circ. Res. 92 (2003) 561-568
38. Ding K., Lopez-Burks M., Sánchez-Duran J.A., Korc M., and Lander A.D. Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J. Cell Biol. 171 (2005) 729-738
39. Echtermeyer F., Streit M., Wilcox-Adelman S., Saoncella S., Denhez F., Detmar M., and Goetinck P. Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J. Clin. Invest. 107 (2001) R9-R14
40. Elenius K., Vainio S., Laato M., Salmivirta M., Thesleff I., and Jalkanen M. Induced expression of syndecan in healing wounds. J. Cell Biol. 114 (1991) 585-595
41. Elenius V., Gotte M., Reizes O., Elenius K., and Bernfield M. Inhibition by the soluble syndecan-1 ectodomains delays wound repair in mice overexpressing syndecan-1. J. Biol. Chem. 279 (2004) 41928-41935
42. Elzie C.A., and Murphy-Ullrich J.E. The N-terminus of thrombospondin: the domain stands apart. Int. J. Biochem. Cell Biol. 36 (2004) 1090-1101
43. Endo C., Kusachi S., Ninomiya Y., Yamamoto K., Murakami M., Murakami T., Shinji T., Koide N., Kondo J., and Tsuji T. Time-dependent increases in syndecan-1 and fibroglycan messenger RNA expression in the infarct zone after experimentally induced myocardial infarction in rats. Coron. Artery Dis. 8 (1997) 155-161
44. Ethell I.M., and Yamaguchi Y. Cell surface heparan sulfate proteoglycan syndecan-2 induces the maturation of dendritic spines in rat hippocampal neurons. J. Cell Biol. 144 (1999) 575-586
45. Ethell I.M., Irie F., Kalo M.S., Couchman J.R., Pasquale E.B., and Yamaguchi Y. EphB/syndecan-2 signaling in dendritic spine morphogenesis. Neuron 31 (2001) 1001-1013
46. Fears C.Y., Grammer J.R., Stewart Jr. J.E., Annis D.S., Mosher D.F., Bornstein P., and Gladson C.L. Low-density lipoprotein receptor-related protein contributes to the antiangiogenic activity of thrombospondin-2 in a murine glioma model. Cancer Res. 65 (2005) 9338-9346
47. Fears C.Y., Gladson C.L., and Woods A. Syndecan-2 is expressed in the microvasculature of mouse gliomas and regulates angiogenesis in microvascular endothelial cells. J. Biol. Chem. 281 (2006) 14533-14536
48. Ferrari do Outeiro-Bernstein M.A., Nunes S.S., Andrade A.C., Alves T.R., Legrand C., and Morandi V. A recombinant NH(2)-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: a possible role for syndecan-4 proteoglycan. Matrix Biol. 21 (2002) 311-324
49. Filla M.S., Dam P., and Rapraeger A.C. The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity. J. Cell. Physiol. 174 (1998) 310-321
50. Finsen A.V., Woldbaek P.R., Li J., Wu J., Lyberg T., Tonnessen T., and Christensen G. Increased syndecan expression following myocardial infarction indicates a role in cardiac remodeling. Physiol. Genomics 16 (2004) 301-308
51. Fitzgerald M.L., Wang Z., Park P.W., Murphy G., and Bernfield M. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J. Cell Biol. 148 (2000) 811-824
52. Folkman J. Fundamental concepts of the angiogenic process. Curr. Mol. Med. 3 (2003) 643-651
53. Freissler E., Meyer auf der Heyde A., David G., Meyer T.F., and Dehio C. Syndecan-1 and syndecan-4 can mediate the invasion of OpaHSPG-expressing Neisseria gonorrhoeae into epithelial cells. Cell. Microbiol. 2 (2000) 69-82
54. Fujiya M., Watari J., Ashida T., Honda M., Tanabe H., Fujiki T., Saitoh Y., and Kohgo Y. Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn. J. Cancer Res. 92 (2001) 1074-1081
55. Fuki I.V., Kuhn K.M., Lomazov I.R., Rothman V.L., Tuszynski G.P., Iozzo R.V., Swenson T.L., Fisher E.A., and Williams K.J. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J. Clin. Invest. 100 (1997) 1611-1622
56. Fuki I.V., Meyer M.E., and Williams K.J. Transmembrane and cytoplasmic domains of syndecan mediate a multi-step endocytic pathway involving detergent-insoluble membrane rafts. Biochem. J. 351 (2000) 607-612
57. Gallay P. Syndecans and HIV-1 pathogenesis. Microbes Infect. 6 (2004) 617-622
58. Gallo R., Kim C., Kokenyesi R., Adzick N.S., and Bernfield M. Syndecans-1 and -4 are induced during wound repair of neonatal but not fetal skin. J. Invest. Dermatol. 107 (1996) 676-683
59. Giroglou T., Florin L., Schafer F., Streeck R.E., and Sapp M. Human papillomavirus infection requires cell surface heparan sulfate. J. Virol. 75 (2001) 1565-1570
60. Gospodarowicz D., and Cheng J. Heparin protects basic and acidic FGF from inactivation. J. Cell. Physiol. 128 (1986) 475-484
61. Gould S.E., Upholt W.B., and Kosher R.A. Syndecan 3: a member of the syndecan family of membrane intercalated proteoglycans that is expressed in high amounts at the onset of chicken limb cartilage differentiation. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 3271-3275
62. Gould S.E., Upholt W.B., and Kosher R.A. Characterization of chicken syndecan-3 as a heparan sulfate proteoglycan and its expression during embryogenesis. Dev. Biol. 168 (1995) 438-451
63. Goutebroze L., Carnaud M., Denisenko N., Boutterin M.C., and Girault J.A. Syndecan-3 and syndecan- 4 are enriched in Schwann cell perinodal processes. B.M.C. Neurosci. 4 (2003) 29
64. Granés F., Garcia R., Casaroli-Marano R.P., Castel S., Rocamora N., Reina M., Ureña J.M., and Vilaró S. Syndecan-2 induces filopodia by active cdc42Hs. Exp. Cell Res. 248 (1999) 439-456
65. Greene D.K., Tumova S., Couchman J.R., and Woods A. Syndecan-4 associates with alpha-actinin. J. Biol. Chem. 278 (2003) 7617-7623
66. Grootjans J.J., Zimmermann P., Reekmans G., Smets A., Degeest G., Durr J., and David G. Syntenin, a PDZ protein that binds syndecan cytoplasmic domains. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 13683-13688
67. Gulyas M., and Hjerpe A. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium. J. Pathol. 199 (2003) 479-487
68. Halden Y., Rek A., Atzenhofer W., Szilak L., Wabnig A., and Kungl A.J. Interleukin-8 binds to syndecan-2 on human endothelial cells. Biochem. J. 15 (2004) 533-538
69. Hamon M., Mbemba E., Charnaux N., Slimani H., Brule S., Saffar L., Vassy R., Prost C., Lievre N., Starzec A., and Gattegno L. A syndecan-4/CXCR4 complex expressed on human primary lymphocytes and macrophages and HeLa cell line binds the CXC chemokine stromal cell-derived factor-1 (SDF-1). Glycobiology 14 (2004) 311-323
70. Han I., Park H., and Oh E.S. New insights into syndecan-2 expression and tumourigenic activity in colon carcinoma cells. J. Mol. Histol. 35 (2004) 319-326
71. Harada K., Masuda S., Hirano M., and Nakanuma Y. Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum. Pathol. 34 (2003) 857-863
72. Henry-Stanley M.J., Hess D.J., Erickson E.A., Garni R.M., and Wells C.L. Role of heparan sulfate in interactions of Listeria monocytogenes with enterocytes. Med. Microbiol. Immunol. (Berl.) 192 (2003) 107-115
73. Henry-Stanley M.J., Hess D.J., Erlandsen S.L., and Wells C.L. Ability of the heparan sulfate proteoglycan syndecan-1 to participate in bacterial translocation across the intestinal epithelial barrier. Shock 24 (2005) 571-576
74. Hinkes M.T., Goldberger O.A., Neumann P.E., Kokenyesi R., and Bernfield M. Organization and promoter activity of the mouse syndecan-1 gene. J. Biol. Chem. 268 (1993) 11440-11448
75. Höök M., Kjellén L., Johansson S., and Robinson J. Cell surface glycosaminoglycans. Ann. Rev. Biochem. 53 (1984) 847-869
76. Horowitz A., and Simons M. Phosphorylation of the cytoplasmic tail of syndecan-4 regulates activation of protein kinase Calpha. J. Biol. Chem. 273 (1998) 25548-25551
77. Horowitz A., Tkachenko E., and Simons M. Fibroblast growth factor-specific modulation of cellular response by syndecan-4. J. Cell Biol. 157 (2002) 715-725
78. Huang W., Chiquet-Ehrismann R., Moyano J.V., Garcia-Pardo A., and Orend G. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res. 61 (2001) 8586-8594
79. Inki P., Joensuu H., Grenman R., Klemi P., and Jalkanen M. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br. J. Cancer 70 (1994) 319-323
80. Ishiguro K., Kadomatsu K., Kojima T., Muramatsu H., Nakamura E., Ito M., Nagasaka T., Kobayashi H., Kusugami K., Saito H., and Muramatsu T. Syndecan-4 deficiency impairs the fetal vessels in the placental labyrinth. Dev. Dyn. 219 (2000) 539-544
81. Joensuu H., Anttonen A., Eriksson M., Makitaro R., Alfthan H., Kinnula V., and Leppa S. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res. 62 (2002) 5210-5217
82. Juuti A., Nordling S., Lundin J., Louhimo J., and Haglund C. Syndecan-1 expression - a novel prognostic marker in pancreatic cancer. Oncology 68 (2005) 97-106
83. Kainulainen V., Wang H., Schick C., and Bernfield M. Syndecans, heparan sulfate proteoglycans, maintain the proteolytic balance of acute wound fluids. J. Biol. Chem. 273 (1998) 11563-11569
84. Kato M., Wang H., Kainulainen V., Fitzgerald M.L., Ledbetter S., Ornitz D.M., and Bernfield M. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat. Med. 4 (1998) 691-697
85. Kim H.R., Choi M.S., and Kim I.S. Role of Syndecan-4 in the cellular invasion of Orientia tsutsugamushi. Microb. Pathog. 36 (2004) 219-225
86. Kiviniemi J., Kallajoki M., Kujala I., Matikainen M.T., Alanen K., Jalkanen M., and Salmivirta M. Altered expression of syndecan-1 in prostate cancer. APMIS 112 (2004) 89-97
87. Klass C.M., Couchman J.R., and Woods A. Control of extracellular matrix assembly by syndecan-2 proteoglycan. J. Cell Sci. 113 (2000) 493-506
88. Kojima T., Takagi A., Maeda M., Segawa T., Shimizu A., Yamamoto K., Matsushita T., and Saito H. Syndecan-4 deficiency increases susceptibility to kappa-carrageenan-induced renal damage. Lab. Invest. 81 (2001) 509-516
89. Kosher R.A. Syndecan-3 in limb skeletal development. Microsc. Res. Tech. 43 (1998) 123-130
90. Kramer K.L., and Yost H.J. Ectodermal syndecan-2 mediates left-right axis formation in migrating mesoderm as a cell-nonautonomous Vg1 cofactor. Dev. Cell 2 (2002) 115-124
91. Kramer K.L., Barnette J.E., and Yost H.J. PKCgamma regulates syndecan-2 inside-out signaling during xenopus left-right development. Cell 111 (2002) 981-990
92. Kusano Y., Yoshitomi Y., Munesue S., Okayama M., and Oguri K. Cooperation of syndecan-2 and syndecan-4 among cell surface heparan sulfate proteoglycans in the actin cytoskeletal organization of Lewis lung carcinoma cells. J. Biochem. (Tokyo) 135 (2004) 129-137
93. Lebakken C.S., and Rapraeger A.C. Syndecan-1 mediates cell spreading in transfected human lymphoblastoid (Raji) cells. J. Cell Biol. 132 (1996) 1209-1221
94. Leivonen M., Lundin J., Nordling S., von Boguslawski K., and Haglund C. Prognostic value of syndecan-1 expression in breast cancer. Oncology 67 (2004) 11-18
95. Li J., Partovian C., Li J., Hampton T.G., Metais C., Tkachenko E., Sellke F.W., and Simons M. Modulation of microvascular signaling by heparan sulfate matrix: studies in syndecan-4 transgenic mice. Microvasc. Res. 64 (2002) 38-46
96. Li L., Couse T.L., Deleon H., Xu C.P., Wilcox J.N., and Chaikof E.L. Regulation of syndecan-4 expression with mechanical stress during the development of angioplasty-induced intimal thickening. J. Vasc. Surg. 36 (2002) 361-370
97. Li J., Zhang Y.P., and Kirsner R.S. Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microsc. Res. Tech. 60 (2003) 107-114
98. Lim S.T., Longley R.L., Couchman J.R., and Woods A. Direct binding of syndecan-4 cytoplasmic domain to the catalytic domain of protein kinase C alpha (PKC alpha) increases focal adhesion localization of PKC alpha. J. Biol. Chem. 278 (2003) 13795-13802
99. Lin F., Ren X.D., Doris G., and Clark R.A. Three-dimensional migration of human adult dermal fibroblasts from collagen lattices into fibrin/fibronectin gels requires syndecan-4 proteoglycan. J. Invest. Dermatol. 124 (2005) 906-913
100. Lindahl U., and Höök M. Glycosaminoglycans and their binding to biological macromolecules. Ann. Rev. Biochem. 47 (1978) 385-417
101. Longley R.L., Woods A., Fleetwood A., Cowling G.J., Gallagher J.T., and Couchman J.R. Control of morphology, cytoskeleton and migration by syndecan-4. J. Cell Sci. 112 (1999) 3421-3431
102. Lovell R., Dunn J.A., Begum G., Barth N.J., Plant T., Moss P.A., Drayson M.T., and Pratt G. Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival. Brit. J. Haematol. 130 (2005) 542-548
103. Lundin M., Nordling S., Lundin J., Wiksten J.-P., and Haglund C. Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology 68 (2005) 306-313
104. Luo J.D., and Chen A.F. Nitric oxide: a newly discovered function on wound healing. Acta Pharmacol. Sin. 26 (2005) 259-264
105. Maeda T., Alexander C.M., and Friedl A. Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res. 64 (2004) 612-621
106. Maeda T., Desouky J., and Friedl A. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 2 (2006) 1408-1412
107. Martin P. Wound healing-aiming for perfect skin regeneration. Science 276 (1997) 75-81
108. Marshall L.J., Ramdin L.S., Brooks T., DPhil P.C., and Shute J.K. Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J. Immunol. 171 (2003) 2057-2065
109. Midwood K.S., Valenick L.V., Hsia H.C., and Schwarzbauer J.E. Coregulation of fibronectin signaling and matrix contraction by tenascin-C and syndecan-4. Mol. Biol. Cell 15 (2004) 5670-5677
110. Miturski R., Jalkanen M., Postawski K., Jakowicki J., and Inki P. Immunohistochemical expression of syndecan-1 in human endometrial cancer cells. Int. J. Mol. Med. 2 (1998) 397-401
111. Modrowski D., Basle M., Lomri A., and Marie P.J. Syndecan-2 is involved in the mitogenic activity and signaling of granulocyte-macrophage colony-stimulating factor in osteoblasts. J. Biol. Chem. 275 (2000) 9178-9185
112. Modrowski D., Orosco A., Thevenard J., Fromigue O., and Marie P.J. Syndecan-2 overexpression induces osteosarcoma cell apoptosis: Implication of syndecan-2 cytoplasmic domain and JNK signaling. Bone 37 (2005) 180-189
113. Mukunyadzi P., Liu K., Hanna E.Y., Suen J.Y., and Fan C.Y. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma. Mod. Pathol. 16 (2003) 796-801
114. Mundhenke C., Meyer K., Drew S., and Friedl A. Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am. J. Pathol. 160 (2002) 185-194
115. Munesue S., Kusano Y., Oguri K., Itano N., Yoshitomi Y., Nakanishi H., Yamashina I., and Okayama M. The role of syndecan-2 in regulation of actin-cytoskeletal organization of Lewis lung carcinoma-derived metastatic clones. Biochem. J. 363 (2002) 201-209
116. Murakami M., Horowitz A., Tang S., Ware J.A., and Simons M. Protein kinase C (PKC) delta regulates PKCalpha activity in a syndecan-4-dependent manner. J. Biol. Chem. 277 (2002) 20367-20371
117. Murphy-Ullrich J.E. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state?. J. Clin. Invest. 107 (2001) 785-790
118. Naganuma H., Satoh E., Asahara T., Amagasaki K., Watanabe A., Satoh H., Kuroda K., Zhang L., and Nukui H. Quantification of thrombospondin-1 secretion and expression of alphavbeta3 and alpha3beta1 integrins and syndecan-1 as cell-surface receptors for thrombospondin-1 in malignant glioma cells. J. Neurooncol. 70 (2004) 309-317
119. Numa F., Hirabayashi K., Kawasaki K., Sakaguchi Y., Sugino N., Suehiro Y., Suminami Y., Hirakawa H., Umayahara K., Nawata S., Ogata H., and Kato H. Syndecan-1 expression in cancer of the uterine cervix: association with lymph node metastasis. Int. J. Oncol. 20 (2002) 39-43
120. Oh E.S., and Couchman J.R. Syndecans-2 and -4; close cousins, but not identical twins. Mol. Cells 17 (2004) 181-187
121. Oh E.S., Woods A., and Couchman J.R. Multimerization of the cytoplasmic domain of syndecan-4 is required for its ability to activate protein kinase C. J. Biol. Chem. 272 (1997) 11805-11811
122. Oh E.S., Woods A., and Couchman J.R. Syndecan-4 proteoglycan regulates the distribution and activity of protein kinase C. J. Biol. Chem. 272 (1997) 8133-8136
123. Oh E.S., Woods A., Lim S.T., Theibert A.W., and Couchman J.R. Syndecan-4 proteoglycan cytoplasmic domain and phosphatidylinositol 4,5-bisphosphate coordinately regulate protein kinase C activity. J. Biol. Chem. 273 (1998) 10624-10629
124. Orr A.W., Elzie C.A., Kucik D.F., and Murphy-Ullrich J.E. Thrombospondin signaling through the calreticulin/LDL receptor-related protein co-complex stimulates random and directed cell migration. J. Cell Sci. 116 (2003) 2917-2927
125. Park P.W., Pier G.B., Preston M.J., Goldberger O., Fitzgerald M.L., and Bernfield M. Syndecan-1 shedding is enhanced by LasA, a secreted virulence factor of Pseudomonas aeruginosa. J. Biol. Chem. 275 (2000) 3057-3064
126. Park P.W., Pier G.B., Hinkes M.T., and Bernfield M. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature 411 (2001) 98-102
127. Park H., Kim Y., Lim Y., Han I., and Oh E.S. Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J. Biol. Chem. 277 (2002) 29730-29736
128. Park P.W., Foster T.J., Nishi E., Duncan S.J., Klagsbrun M., and Chen Y. Activation of syndecan-1 ectodomain shedding by Staphylococcus aureus alpha-toxin and beta-toxin. J. Biol. Chem. 279 (2004) 251-258
129. Pierson T.C., and Doms R.W. HIV-1 entry and its inhibition. Curr. Top. Microbiol. Immunol. 281 (2003) 1-27
130. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., and Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16 (2005) 159-178
131. Rapraeger A., Jalkanen M., Endo E., Koda J., and Bernfield M. The cell surface proteoglycan from mouse mammary epithelial cells bears chondroitin sulfate and heparan sulfate glycosaminoglycans. J. Biol. Chem. 260 (1985) 11046-11052
132. Raulo E., Chernousov M.A., Carey D.J., Nolo R., and Rauvala H. Isolation of a neuronal cell surface receptor of heparin binding growth-associated molecule (HB-GAM). Identification as N-syndecan (syndecan-3). J. Biol. Chem. 269 (1994) 12999-13004
133. Rege T., Fears C.Y., and Gladson C.L. Endogenous inhibitors of angiogenesis in malignant gliomas: nature's anti-angiogenic therapy. J. Neuro-oncol. 7 (2005) 106-121
134. Reizes O., Lincecum J., Wang Z., Goldberger O., Huang L., Kaksonen M., Ahima R., Hinkes M.T., Barsh G.S., Rauvala H., and Bernfield M. Transgenic expression of syndecan-1 uncovers a physiological control of feeding behavior by syndecan-3. Cell 106 (2001) 105-116
135. Reizes O., Benoit S.C., Strader A.D., Clegg D.J., Akunuru S., and Seeley R.J. Syndecan-3 modulates food intake by interacting with the melanocortin/AgRP pathway. Ann. N.Y. Acad. Sci. 994 (2003) 66-73
136. Richardson T.P., Trinkaus-Randall V., and Nugent M.A. Regulation of basic fibroblast growth factor binding and activity by cell density and heparan sulfate. J. Biol. Chem. 274 (1999) 13534-13540
137. Rider C.C. The potential for heparin and its derivatives in the therapy and prevention of HIV-1 infection. Glycoconj. J. 14 (1997) 639-642
138. Sabharanjak S., Sharma P., Parton R.G., and Mayor S. GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-independent pinocytic pathway. Dev. Cell 2 (2002) 411-423
139. Saphire A.C., Bobardt M.D., Zhang Z., David G., and Gallay P.A. Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages. J. Virol. 75 (2001) 9187-9200
140. Sanderson R.D., Yang Y., Kelly T., MacLeod V., Dai Y., and Theus A. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J. Cell. Biochem. 96 (2005) 897-905
141. Sebestyen A., Totth A., Mihalik R., Szakacs O., Paku S., and Kopper L. Syndecan-1-dependent homotypic cell adhesion in HT58 lymphoma cells. Tumour Biol. 21 (2000) 349-357
142. Seftalioglu A., and Karakus S. Syndecan-1/CD138 expression in normal myeloid, acute lymphoblastic and myeloblastic leukemia cells. Acta Histochem. 105 (2003) 213-221
143. Seidel C., Sundan A., Hjorth M., Turesson I., Dahl I.M., Abildgaard N., Waage A., and Borset M. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95 (2000) 388-392
144. Selinka H.C., Giroglou T., and Sapp M. Analysis of the infectious entry pathway of human papillomavirus type 33 pseudovirions. Virology 299 (2002) 279-287
145. Shafti-Keramat S., Handisurya A., Kriehuber E., Meneguzzi G., Slupetzky K., and Kirnbauer R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J. Virol. 77 (2003) 13125-13135
146. Shinyo Y., Kodama J., Hasengaowa, Kusumoto T., and Hiramatsu Y. Loss of cell-surface heparan sulfate expression in both cervical intraepithelial neoplasm and invasive cervical cancer. Gynecol. Oncol. 96 (2005) 776-783
147. Simons M., and Horowitz A. Syndecan-4-mediated signalling. Cell. Signal. 13 (2001) 855-862
148. Stepp M.A., Gibson H.E., Gala P.H., Iglesia D.D., Pajoohesh-Ganji A., Pal-Ghosh S., Brown M., Aquino C., Schwartz A.M., Goldberger O., Hinkes M.T., and Bernfield M. Defects in keratinocyte activation during wound healing in the syndecan-1-deficient mouse. J. Cell Sci. 115 (2002) 4517-4531
149. Strader A.D., Reizes O., Woods S.C., Benoit S.C., and Seeley R.J. Mice lacking the syndecan-3 gene are resistant to diet-induced obesity. J. Clin. Invest. 114 (2004) 1354-1360
150. Subramanian S.V., Fitzgerald M.L., and Bernfield M. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J. Biol. Chem. 272 (1997) 14713-14720
151. Tkachenko E., Lutgens E., Stan R.V., and Simons M. Fibroblast growth factor 2 endocytosis in endothelial cells proceed via syndecan-4-dependent activation of Rac1 and a Cdc42-dependent macropinocytic pathway. J. Cell Sci. 117 (2004) 3189-3199
152. Tkachenko E., Rhodes J.M., and Simons M. Syndecans: new kids on the signaling block. Circ. Res. 96 (2005) 488-500
153. Tsanou E., Ioachim E., Briasoulis E., Charchanti A., Damala K., Karavasilis V., Pavlidis N., and Agnantis N.J. Clinicopathological study of the expression of syndecan-1 invasive breast carcinomas. Correlation with extracellular matrix components. J. Exp. Clin. Cancer Res. 23 (2004) 641-650
154. Vassilakopoulos T.P., Kyrtsonis M.C., Papadogiannis A., Nadali G., Angelopoulou M.K., Tzenou T., Dimopoulou M.N., Siakantaris M.P., Kontopidou F.N., Kalpadakis C., Kokoris S.I., Dimitriadou E.M., Tsaftaridis P., Pizzolo G., and Pangalis G.A. Serum levels of soluble syndecan-1 in Hodgkin's lymphoma. Anticancer Res. 25 (2005) 4743-4746
155. Villena J., Berndt C., Granés F., Reina M., and Vilaró S. Syndecan-2 expression enhances adhesion and proliferation of stably transfected Swiss 3T3 cells. Cell Biol. Int. 27 12 (2003) 1005-1010
156. Volk R., Schwartz J.J., Li J., Rosenberg R.D., and Simons M. The role of syndecan cytoplasmic domain in basic fibroblast growth factor-dependent signal transduction. J. Biol. Chem. 274 (1999) 24417-24424
157. Wang S., Herndon M.E., Ranganathan S., Godyna S., Lawler J., Argraves W.S., and Liau G. Internalization but not binding of thrombospondin-1 to low density lipoprotein receptor-related protein-1 requires heparan sulfate proteoglycans. J. Cell. Biochem. 91 (2004) 766-776
158. Wang Z., Gotte M., Bernfield M., and Reizes O. Constitutive and accelerated shedding of murine syndecan-1 is mediated by cleavage of its core protein at a specific juxtamembrane site. Biochemistry 44 (2005) 12355-12361
159. Wiksten J.P., Lundin J., Nordling S., Lundin M., Kokkola A., von Boguslawski K., and Haglund C. Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int. J. Cancer 95 (2001) 1-6
160. Woods A., and Couchman J.R. Focal adhesions and cell-matrix interactions. Collagen Relat. Res. 8 (1988) 155-182
161. Woods A., and Couchman J.R. Syndecan-4 and focal adhesion function. Curr. Opin. Cell Biol. 13 (2001) 578-583
162. Woods A., Longley R.L., Tumova S., and Couchman J.R. Syndecan-4 binding to the high affinity heparin-binding domain of fibronectin drives focal adhesion formation in fibroblasts. Arch. Biochem. Biophys. 374 (2000) 66-72
163. Worapamorn W., Xiao Y., Li H., Young W.G., and Bartold P.M. Differential expression and distribution of syndecan-1 and -2 in periodontal wound healing of the rat. J. Periodontal Res. 37 (2002) 293-299
164. Yang Y., Yaccoby S., Liu W., Langford J.K., Pumphrey C.Y., Theus A., Epstein J., and Sanderson R.D. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 100 (2002) 610-617
165. Yoneda A., and Couchman J.R. Regulation of cytoskeletal organization by syndecan transmembrane proteoglycans. Matrix Biol. 22 (2003) 25-33
166. Yung S., Woods A., Chan T.M., Davies M., Williams J.D., and Couchman J.R. Syndecan-4 upregulation in proliferative renal disease is related to microfilament organization. FASEB J. 15 (2001) 1631-1633
167. Zellweger T., Ninck C., Mirlacher M., Annefeld M., Glass A.G., Gasser T.C., Mihatsch M.J., Gelmann E.P., and Bubendorf L. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 55 (2003) 20-29
168. Zellweger T., Ninck C., Bloch M., Mirlacher M., Koivisto P.A., Helin H.J., Mihatsch M.J., Gasser T.C., and Bubendorf L. Expression patterns of potential therapeutic targets in prostate cancer. Int. J. Cancer 113 (2005) 619-628
169. Zhang Y., Li J., Partovian C., Sellke F.W., and Simons M. Syndecan-4 modulates basic fibroblast growth factor 2 signaling in vivo. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H2078-H2082